Abbott ABT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Diagnostic Products | $9.06B+1.4% | $8.94B-0.7% | $9B-1.7% | $9.16B-0.2% | $9.18B-1.7% | |
| Established Pharmaceuticals | $5.7B+3.0% | $5.54B+2.1% | $5.42B+2.0% | $5.32B+1.7% | $5.23B+0.7% | |
| Medical Devices | $22.03B+3.0% | $21.39B+3.0% | $20.76B+3.5% | $20.06B+3.3% | $19.43B+2.3% | |
| Nutritional Products | $8.32B-1.5% | $8.45B-2.2% | $8.64B+1.0% | $8.55B+0.7% | $8.49B+0.9% | |
| Total Assets by Business | ||||||
| Diagnostic Products | $34.28B+5.5% | $32.49B+1.9% | $31.9B— | —— | —— | |
| Established Pharmaceuticals | $14.67B+1.5% | $14.45B+3.2% | $14B— | —— | —— | |
| Medical Devices | $42.8B+2.3% | $41.85B+3.0% | $40.64B— | —— | —— | |
| Nutritional Products | $19.5B+1.4% | $19.23B+2.1% | $18.84B— | —— | —— | |
| Operating Earnings by Business | ||||||
| Diagnostic Products | $1.72B-1.4% | $1.74B-0.1% | $1.74B-8.3% | $1.9B-3.0% | $1.96B-5.5% | |
| Established Pharmaceuticals | $1.36B+5.2% | $1.29B-1.2% | $1.31B+0.8% | $1.3B+2.5% | $1.26B+2.5% | |
| Medical Devices | $7.5B+3.9% | $7.21B+2.9% | $7.01B+4.7% | $6.69B+4.5% | $6.4B+4.0% | |
| Nutritional Products | $1.48B-5.3% | $1.56B-3.5% | $1.62B+3.1% | $1.57B+3.0% | $1.52B+1.1% | |
| Selling, general, and administrative by Business | ||||||
| Diagnostic Products | $1.67B+3.5% | $1.61B-1.7% | $1.64B+0.2% | $1.64B+1.4% | $1.61B-0.3% | |
| Established Pharmaceuticals | $1.48B+1.7% | $1.46B+3.6% | $1.41B+2.0% | $1.38B+1.4% | $1.36B+1.3% | |
| Medical Devices | $5.55B+1.9% | $5.45B+2.4% | $5.32B+3.3% | $5.15B+3.3% | $4.99B+2.2% | |
| Nutritional Products | $2.1B-0.6% | $2.11B-2.5% | $2.17B-1.6% | $2.2B+0.4% | $2.19B+1.2% | |
| Cost of products sold, excluding amortization of intangible assets by Business | ||||||
| Diagnostic Products | -$4.89B+1.8% | -$4.98B+0.3% | -$5B+0.2% | -$5.01B+0.4% | -$5.03B-0.7% | |
| Established Pharmaceuticals | -$2.54B+2.9% | -$2.62B-11.3% | -$2.35B+2.9% | -$2.42B+1.6% | -$2.46B-0.6% | |
| Medical Devices | -$6.76B+3.1% | -$6.97B-15.0% | -$6.06B+2.6% | -$6.23B+2.1% | -$6.36B+0.8% | |
| Nutritional Products | -$4.6B-0.8% | -$4.57B-3.4% | -$4.42B+1.6% | -$4.49B+0.2% | -$4.5B+0.8% | |
| R&D by Business | ||||||
| Diagnostic Products | $606M+0.7% | $602M-4.3% | $629M-2.3% | $644M-1.2% | $652M-0.6% | |
| Established Pharmaceuticals | $175M-0.6% | $176M+2.3% | $172M-2.3% | $176M-0.6% | $177M+0.6% | |
| Medical Devices | $1.8B+2.5% | $1.75B+4.1% | $1.68B+3.3% | $1.63B+3.2% | $1.58B+2.1% | |
| Nutritional Products | $215M+0.9% | $213M+0.5% | $212M+1.0% | $210M+0.5% | $209M0.0% | |
| Additions to Property and Equipment by Business | ||||||
| Diagnostic Products | $754M-0.9% | $761M+1.2% | $752M-2.0% | $767M-0.4% | $770M+1.6% | |
| Established Pharmaceuticals | $156M-7.7% | $169M-3.4% | $175M-7.4% | $189M+1.1% | $187M+2.2% | |
| Medical Devices | $649M-1.4% | $658M+4.9% | $627M-1.7% | $638M-2.0% | $651M+3.3% | |
| Nutritional Products | $263M-12.9% | $302M-8.8% | $331M-9.6% | $366M-5.7% | $388M+1.6% | |
| Remaining performance obligations by Business | ||||||
| Diagnostic Products | $24.2B+2.1% | $23.7B+2.6% | $23.1B+3.1% | $22.4B+5.2% | $21.3B+6.0% | |
| Medical Devices | $1.74B+0.3% | $1.73B+0.2% | $1.73B-1.7% | $1.76B-3.6% | $1.82B-3.8% | |
| Depreciation by Business | ||||||
| Diagnostic Products | $551M+3.4% | $533M+0.4% | $531M+1.3% | $524M+1.2% | $518M-0.6% | |
| Established Pharmaceuticals | $108M+6.9% | $101M0.0% | $101M+5.2% | $96M+1.1% | $95M-1.0% | |
| Medical Devices | $390M+3.2% | $378M+4.7% | $361M+2.8% | $351M+2.0% | $344M+0.3% | |
| Nutritional Products | $183M+4.6% | $175M-0.6% | $176M+5.4% | $167M+3.1% | $162M+1.9% | |
| Goodwill, non-deductible by Business | ||||||
| Diagnostic Products | $25.7B+79.7% | $14.3B+0.7% | $14.2B0.0% | $14.2B+0.7% | $14.1B0.0% | |
| Established Pharmaceuticals | $10.8B+0.9% | $10.7B+0.9% | $10.6B0.0% | $10.6B+1.0% | $10.5B-0.9% | |
| Medical Devices | $69.4B+0.6% | $69B+0.9% | $68.4B+0.4% | $68.1B+0.6% | $67.7B0.0% | |
| Nutritional Products | $1.16B+1.3% | $1.14B0.0% | $1.14B0.0% | $1.14B0.0% | $1.14B0.0% | |
| Net Sales by Geography | ||||||
| International | $27.9B+2.6% | $27.2B+1.7% | $26.76B+2.4% | $26.12B+1.6% | $25.7B+0.3% | |
| United States | $17.23B+0.6% | $17.13B+0.2% | $17.08B+0.6% | $16.99B+2.1% | $16.65B+2.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Abbott break its business down?
- Abbott (ABT) reports net sales by business across 4 parts — Diagnostic Products, Established Pharmaceuticals, Medical Devices and Nutritional Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Abbott's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Abbott's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
